Meeting
2016 ASCO Annual Meeting
A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.
Authors
Thomas Powles
Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Thomas Powles , Matt D. Galsky , Daniel Castellano , Michiel Simon Van Der Heijden , Daniel Peter Petrylak , Jon Armstrong , Riccardo Belli , Salvatore Ferro , Yong Ben , Joaquim Bellmunt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT02516241
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS4574)
DOI
10.1200/JCO.2016.34.15_suppl.TPS4574
Abstract #
TPS4574
Poster Bd #
196a
Abstract Disclosures
Similar Posters
First Author: Matt D. Galsky
Poster
2019 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
First Author: Matt D. Galsky
Poster
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).
First Author: Matt D. Galsky
Poster
2016 ASCO Annual Meeting
A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.
First Author: Tanguy Y. Seiwert